CSIMarket
 


Takeda Pharmaceutical Company Limited  (TAK)
Other Ticker:  
 

Takeda Pharmaceutical Limited's Tangible Leverage Ratio

TAK's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to repayements of liabilities of 0% Takeda Pharmaceutical Limited improved Tangible Leverage Ratio in forth quarter 2023 to 4.86, above the Takeda Pharmaceutical Limited's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 362 other companies have achieved lower Tangible Leverage Ratio than Takeda Pharmaceutical Limited in the IV Quarter 2023. While Tangible Leverage Ratio total ranking has deteriorated compared to the third quarter 2023 from 2198 to 2236 .

Explain Tangible Leverage Ratio?
What is TAK Market Share?
What are TAK´s Total Liabilities?


TAK Tangible Leverage Ratio (Mar 31 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Mar 31 2021)
IV. Quarter
Y / Y Tangible Equity Change 5.29 % 5.29 % 5.29 % 5.29 % -
Y / Y Total Liabilities Change -24.35 % -24.35 % -24.35 % -24.35 % -
Tangible Leverage Ratio MRQ 4.86 4.86 4.86 4.86 6.77
TAK's Total Ranking # 2236 # 2198 # 2198 # 2198 # 0
Seq. Tangible Equity Change 0 % 0 % 0 % 5.29 % 0 %
Seq. Total Liabilities Change 0 % 0 % 0 % -24.35 % 0 %



Tangible Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 363
Healthcare Sector # 711
Overall Market # 2236


Tangible Leverage Ratio Statistics
High Average Low
1.49 1.35 1.2
(Mar 31 2021)   (Mar 31 2023)




Financial Statements
Takeda Pharmaceutical Limited's Tangible Equity $ 10,835 Millions Visit TAK's Balance sheet
Takeda Pharmaceutical Limited's Total Liabilities $ 52,674 Millions Visit TAK's Balance sheet
Source of TAK's Sales Visit TAK's Sales by Geography


Cumulative Takeda Pharmaceutical Limited's Tangible Leverage Ratio

TAK's Tangible Leverage Ratio for the trailling 12 Months

TAK Tangible Leverage Ratio

(Mar 31 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Mar 31 2021)
IV. Quarter
Y / Y Tangible Equity TTM Growth 5.29 % 5.29 % 5.29 % 5.29 % -
Y / Y Total Liabilities TTM Growth -24.35 % -24.35 % -24.35 % -24.35 % -
Tangible Leverage Ratio TTM 4.86 5.32 5.79 6.27 6.77
Total Ranking TTM # 107 # 121 # 122 # 0 # 0
Seq. Tangible Equity TTM Growth 0 % 0 % 0 % 5.29 % 0 %
Seq. Total Liabilities TTM Growth 0 % 0 % 0 % -24.35 % 0 %


On the trailing twelve months basis Due to repayements of liabilities of 0% Takeda Pharmaceutical Limited decreased Tangible Leverage Ratio in the 12 months ending in IV Quarter 2023 to 4.86, above the Takeda Pharmaceutical Limited's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 11, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Takeda Pharmaceutical Limited. While Tangible Leverage Ratio total ranking has improved so far to 107, from total ranking in previous 12 month period at 121.

Explain Tangible Leverage Ratio?
What is TAK Market Share?
What are TAK´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 12
Healthcare Sector # 30
Within the Market # 107


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.9 0.8 0.65
(Mar 31 2021)   (Mar 31 2023)




Companies with similar Tangible Leverage Ratio in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioMar 31 2023 MRQ Total LiabilitiesMar 31 2023 MRQ Tangible Equity
Lifecore Biomedical Inc   12.68 $ 201.946  Millions$ 15.926  Millions
Pfizer Inc  11.84 $ 91,830.000  Millions$ 7,758.000  Millions
Ocular Therapeutix Inc   10.03 $ 97.408  Millions$ 9.711  Millions
Pacira Biosciences inc   9.61 $ 755.377  Millions$ 78.574  Millions
Ani Pharmaceuticals Inc  9.46 $ 450.592  Millions$ 47.620  Millions
Catalent Inc   9.17 $ 6,127.000  Millions$ 668.000  Millions
Merck and Co Inc   8.78 $ 51,276.000  Millions$ 5,839.000  Millions
Cumberland Pharmaceuticals Inc  8.43 $ 48.401  Millions$ 5.744  Millions
Supernus Pharmaceuticals inc   7.81 $ 879.658  Millions$ 112.634  Millions
Societal Cdmo Inc   7.27 $ 88.394  Millions$ 12.155  Millions
Abbott Laboratories  6.83 $ 29,367.000  Millions$ 4,299.000  Millions
Omeros Corp  6.56 $ 360.400  Millions$ 54.936  Millions
Intercept Pharmaceuticals inc   6.50 $ 436.900  Millions$ 67.185  Millions
Axsome Therapeutics Inc   6.39 $ 277.367  Millions$ 43.413  Millions
Tg Therapeutics Inc   6.00 $ 159.846  Millions$ 26.634  Millions
Orgenesis Inc   5.59 $ 64.264  Millions$ 11.504  Millions
Panbela Therapeutics Inc   5.50 $ 13.940  Millions$ 2.535  Millions
Veru Inc   5.47 $ 53.538  Millions$ 9.795  Millions
Maravai Lifesciences Holdings Inc   5.40 $ 1,793.871  Millions$ 332.491  Millions
Dar Bioscience Inc   5.11 $ 25.395  Millions$ 4.972  Millions
Clearmind Medicine Inc   5.05 $ 4.970  Millions$ 0.983  Millions
Ionis Pharmaceuticals Inc  4.93 $ 2,398.651  Millions$ 486.570  Millions
Horizon Therapeutics Public Limited Company  4.91 $ 3,429.118  Millions$ 698.859  Millions
Takeda Pharmaceutical Company Limited  4.86 $ 52,674.052  Millions$ 10,835.024  Millions
Abvc Biopharma Inc   4.82 $ 8.353  Millions$ 1.735  Millions
Emergent Biosolutions Inc   4.65 $ 1,747.200  Millions$ 375.500  Millions
Apexigen Inc   4.65 $ 14.463  Millions$ 3.113  Millions
Durect Corp  4.59 $ 42.086  Millions$ 9.173  Millions
China Pharma Holdings Inc   4.46 $ 12.687  Millions$ 2.843  Millions
Pieris Pharmaceuticals Inc   4.32 $ 66.800  Millions$ 15.458  Millions

Date modified: 2023-06-28T20:12:23+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com